CYCLE 1A Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Phase Difference = Phase Difference = 0.05.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Time (days) A % Overall Survival Time (days) % Overall Survival SUPPLEMENTAL FIGURE 1 Legend: MMTV-Cre, n = 71 R26(Pik3ca), n = 285 R26(Stat3), n = 46.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Table 1. Patient Characteristics

Intention-to-treat population

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Tips Need to Consider When Organizing a College Event

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Prolonging Progression-Free Survival in Follicular Lymphoma

ماجستير إدارة المعارض من بريطانيا

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma Egil S. Blix, Anders.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma Egil S. Blix, Anders.

Table 2. Progression-Free Survival

EDLC(Embedded system Development Life Cycle ).

A B Yeom Supplementary Fig.2

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study Rena Buckstein,

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Supplemental Figure 1A Pt Pt Pre-treatment

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

Supplemental Figure untreated Rituximab Alemtuzumab

Volume 375, Issue 9709, Pages (January 2010)

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Mary.

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Volume 21, Issue 7, Pages (July 2013)

Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease.

Supplemental Figure 6 Effect of p. o

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma

High CDK6 expression predicts poor prognosis in EOC patients

High volume Low volume HORRAD STAMPEDE Failure-free survival

Supplementary Figure S1

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Time to Recurrence (Hormone Receptor-positive Patients)

Diagonal lines were shown.

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Autologous Stem Cell Transplantation for POEMS Syndrome

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia by Susan M. O'Brien, Nicole Lamanna, Thomas.

Presentation transcript:

CYCLE 1A Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years ALC/AMC ≥ 1.1, N =146 Events = 2 ALC/AMC < 1.1, N =44 Events = 16 HR: 0.03, 95% CI (0.005-0.11), P < 0.0001 Lymphoma-specific survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =146 Events = 17 ALC/AMC < 1.1, N =44 Events = 24 HR: 0.15, 95% CI (0.08-0.29), P < 0.0001 1 3 5 7 9 11 13 15 17 19 21 Time in years 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Time to progression ALC/AMC ≥ 1.1, N =146 Events = 10 ALC/AMC < 1.1, N =44 Events = 18 HR: 0.11, 95% CI (0.05-0.24), P < 0.0001

CYCLE 1B 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =154 Events = 17 ALC/AMC < 1.1, N =36 Events = 24 HR: 0.10, 95% CI (0.05-0.20), P < 0.0001 Supplemental Figure 1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =154 Events = 2 ALC/AMC < 1.1, N =36 Events = 16 HR: 0.02, 95% CI (0.003-0.08), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =154 Events = 11 ALC/AMC < 1.1, N =36 Events = 17 HR: 0.08, 95% CI (0.04-0.18), P < 0.0001

CYCLE 2A Supplemental Figure 1 1 3 5 7 9 11 13 15 17 19 21 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Progression-free survival Time in years ALC/AMC ≥ 1.1, N =151 Events = 18 ALC/AMC < 1.1, N =39 Events = 13 HR: 0.13, 95% CI (0.07-0.25), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =151 Events = 3 ALC/AMC < 1.1, N =39 Events = 15 HR: 0.04, 95% CI (0.01-0.12), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =151 Events = 11 ALC/AMC < 1.1, N =39 Events = 17 HR: 0.10, 95% CI (0.04-0.21), P < 0.0001

CYCLE 2B Supplemental Figure 1 1.0 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =147 Events = 3 ALC/AMC < 1.1, N =43 Events = 15 HR: 0.04, 95% CI (0.01-0.13), P < 0.0001 0.9 0.8 0.7 ALC/AMC ≥ 1.1, N =147 Events = 18 0.6 Progression-free survival 0.5 ALC/AMC < 1.1, N =43 Events = 23 0.4 0.3 0.2 0.1 HR: 0.15, 95% CI (0.07-0.28), P < 0.0001 0.0 1 3 5 7 9 11 13 15 17 19 21 Time in years 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =147 Events = 10 ALC/AMC < 1.1, N =43 Events = 18 HR: 0.08, 95% CI (0.03-0.19), P < 0.0001

CYCLE 3A Supplemental Figure 1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =135 Events = 14 ALC/AMC < 1.1, N =38 Events = 22 HR: 0.21, 95% CI (0.06-0.24), P < 0.0001 1 3 5 7 9 11 13 15 17 19 21 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =135 Events = 1 ALC/AMC < 1.1, N =38 Events = 14 HR: 0.02, 95% CI (0.001-0.08), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC < 1.1, N =38 Events = 18 ALC/AMC ≥ 1.1, N =135 Events = 9 HR: 0.09, 95% CI (0.04-0.19), P < 0.0001

CYCLE 3B Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =127 Events = 13 ALC/AMC < 1.1, N =46 Events = 23 HR: 0.15, 95% CI (0.07-0.29), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =127 Events = 3 ALC/AMC < 1.1, N =46 Events = 11 HR: 0.11, 95% CI (0.03-0.31), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =127 Events = 9 ALC/AMC < 1.1, N =46 Events = 18 HR: 0.12, 95% CI (0.05-0.27), P < 0.0001

CYCLE 4A Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =122 Events = 4 ALC/AMC < 1.1, N =46 Events = 11 HR: 0.11, 95% CI (0.03-0.34), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =122 Events = 15 ALC/AMC < 1.1, N =46 Events = 20 HR: 0.22, 95% CI (0.11-0.43), P < 0.0001 ALC/AMC ≥ 1.1, N =122 Events = 10 ALC/AMC < 1.1, N =46 Events = 17 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression HR: 0.16, 95% CI (0.07-0.36), P < 0.0001

CYCLE 4B Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =125 Events = 3 ALC/AMC < 1.1, N =43 Events = 11 HR: 0.08, 95% CI (0.02-0.24), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =125 Events = 16 ALC/AMC < 1.1, N =43 Events = 18 HR: 0.24, 95% CI (0.12-0.47), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =125 Events = 12 ALC/AMC < 1.1, N =43 Events = 15 HR: 0.21, 95% CI (0.09-0.44), P < 0.0001

CYCLE 5A Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =90 Events = 10 ALC/AMC < 1.1, N =27 Events = 18 HR: 0.08, 95% CI (0.03-0.18), P < 0.0001 Lymphoma-specific survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years ALC/AMC ≥ 1.1, N =90 Events = 2 ALC/AMC < 1.1, N =27 Events = 9 HR: 0.05, 95% CI (0.01-0.18), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =90 Events = 8 ALC/AMC < 1.1, N =27 Events = 15 HR: 0.07, 95% CI (0.02-0.18), P < 0.0001

CYCLE 5B Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =88 Events = 3 ALC/AMC < 1.1, N =29 Events = 8 HR: 0.09, 95% CI (0.02-0.32), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =88 Events = 13 ALC/AMC < 1.1, N =29 Events = 15 HR: 0.19, 95% CI (0.08-0.40), P < 0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =88 Events = 10 ALC/AMC < 1.1, N =29 Events = 13 HR: 0.15, 95% CI (0.06-0.36), P < 0.0001

CYCLE 6A Supplemental Figure 1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =84 Events = 13 ALC/AMC < 1.1, N =31 Events = 14 HR: 0.25, 95% CI (0.12-0.55), P < 0.0006 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival ALC/AMC ≥ 1.1, N =84 Events = 3 ALC/AMC < 1.1, N =31 Events = 7 HR: 0.12, 95% CI (0.03-0.45), P < 0.0003 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =84 Events = 11 ALC/AMC < 1.1, N =31 HR: 0.25, 95% CI (0.11-0.57), P < 0.001

CYCLE 6B Supplemental Figure 1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Progression-free survival ALC/AMC ≥ 1.1, N =89 Events = 13 ALC/AMC < 1.1, N =28 Events = 14 HR: 0.18, 95% CI (0.08-0.39), P < 0.0001 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Lymphoma-specific survival HR: 0.05, 95% CI (0.01-0.21), P < 0.0001 ALC/AMC ≥ 1.1, N =89 Events = 2 ALC/AMC < 1.1, N =28 Events = 8 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 1 3 5 7 9 11 13 15 17 19 21 Time in years Time to progression ALC/AMC ≥ 1.1, N =89 Events = 11 ALC/AMC < 1.1, N =28 Events = 12 HR: 0.17, 95% CI (0.07-0.41), P < 0.0001

Supplemental Figure Legend Figure 1. Lymphoma-specific survival (LSS), progression-free survival (PFS), and time to progression (TTP) based on the ALC/AMC ratio at each treatment cycle phase. ALC = absolute lymphocyte count and AMC = absolute monocyte count.